Navigation Links
PA Governor's Occupational Safety and Health Conference Still Accepting Registrations
Date:10/5/2007

HARRISBURG, Pa., Oct. 5 /PRNewswire-USNewswire/ -- One of the largest annual health and safety conferences on the East Coast, Pennsylvania's 81st Governor's Occupational Safety and Health Conference, is just around the corner and there's still time to register.

The two-day conference, Oct. 15-16 at the Hershey Lodge & Convention Center, Hershey, draws more than 1,000 safety and health care professionals, business leaders, workers, educators and government leaders from across Pennsylvania and it offers a forum to discuss the importance of workplace safety and how employers are providing safe working places.

This year's conference will feature keynote speakers Randy Snow and Edwin Foulke Jr.

Snow, a nationally known author, sales associate and CEO of NoXQs (No Excuses), will speak about his personal experiences on Oct. 15 with workplace safety, and how he overcame a farming accident that left him without the use of his legs and his continued achievements since his recovery.

Foulke Jr., who heads the Occupational Safety and Health Administration, or OSHA, will speak on Oct. 16 about his involvement with workplace safety and what the federal government is doing to improve workplace conditions across the country.

To register for the Governor's Occupational Safety and Health conference, or for more information, visit http://www.state.pa.us, PA Keyword: workplace safety.

CONTACT: Troy Thompson

717-787-7530


'/>"/>
SOURCE Pennsylvania Department of Labor & Industry
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. The National Governors Association Releases Guidelines For Outbreak Of Bird Flu
2. Occupational exposurer aises respiratory symptoms
3. Occupational Exposure To Radiation Causes Chromosome Aberrations
4. Immune response in Occupational metal fume inhaling workers
5. The Hazard of Occupational Asthma
6. Occupational Therapy Improves Independence in Stroke Survivors
7. Occupational Hazards increase Breast Cancer risk
8. Stroke Patients Benefited by Occupational Therapy
9. Alerts for safety of heart device
10. Surgery a safety in senility
11. Surgery a safety in senility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/9/2009)... New England Peptide, a Massac...ides and polyclonal antibodies for drug and vaccin...customers with alternative chemical solutions in t...eading New England Peptide,s strategic usage of ne...obert Hammer and Dr. Robert Hodges. , ...
(Date:1/8/2009)...OSTON, Jan. 8 The Allia...ngly opposes the new marketing campaigns by Wal-Ma... to provide free prescribed antibiotics to custome...they will actually lead to increased costs in the ...esistance. While the public,s need for affordable...
(Date:1/8/2009)...ALLAS, Jan. 8 A study released thi...are suffering from multiple chronic diseases shine... U.S. health care system to one that focuses on pr...Preventive Medicine, the leader in disease prevent...bin/prnh/20080506/NETU129LOGO ) , , The study...
(Date:1/8/2009)...alifornia Assembly Member Tom Torlakson Introduces...re-USNewswire/ -- Today, Lung Cancer Alliance-Ca...er Tom Torlakson (D-11th District) for his continu... funding for lung cancer research. For the third ... cancer research is being considered in the Califo...
Breaking Medicine News(10 mins):Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 2Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 3Health News:Antibiotics as Loss Leaders? 2Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2
...ty of Southern California in Los Angeles, study th...obese or overweight people and found// that the no...han their obese counterparts. The study that was ...an Dietetic Association stated that the compositio...
...s has gone against the general notion and has show...overstrain the emergency rooms// in hospitals in t...stated that most of the Hispanics were uninsured a...heir conditions worsen to the point where they wou...
...luding Tata Steel have joined hands with the Jhark... Trust to ensure medicare to the state's Below Pov...ed to contribute Rs 25 crore for the said purpose ...sar Group were expected to confirm their respectiv...
...stration (FDA) and Roxane Labs have issued a natio...re used in patients with severe// rheumatoid arthr...revent rejection. "It was discovered that a single...lot 558470A contained Methotrexate tablets USP 2.5...
Other Medicine News:Health News:Better Weight Management Can be Achieved By Increased Intake Of Fibre & Fruits 2
(Date:1/7/2009)... INDIANAPOLIS, Jan. 7 El...y that it received a complete response letter from...olanzapine long-acting,injection (LAI) for acute ...lts. Lilly is continuing to work with the agency o...A does not require any additional clinical trials ...
(Date:1/7/2009)...JING, Jan. 7 Tiantan Puhua Hospita...m ), the worldwide leader in using stem cells to e... today six new globally experienced additions to i...xpand the hospital,s treatment capabilities for gr...The six senior doctors include the distinguished D...
(Date:1/6/2009)... YORK, Jan. 6 The Micha... million to four industry research teams for pre-c...arkinson,s disease. , , The funding was awarded...Initiative. This program, first launched in 2006,... Parkinson,s research. TDI is part of MJFF,s foc...
(Date:1/5/2009)... DIEGO, Jan. 5 Cylene Pharmaceutic...I clinical trial of its oral CK2 protein kinase in...tumors, Castleman,s disease, or multiple myeloma. ...trial are determination of safety, tolerance and P...ate dose for Phase II trials. In addition, multipl...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 1Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 2Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 3TriWest Contributes 2415 000 to Kansas National Guard Fund 8420 1TriWest Contributes 2415 000 to Kansas National Guard Fund 8420 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 1Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 3Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 1Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 2Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 3Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 5
... Data presented at 12th Congress of European Hemat...e-FirstCall/ -- Alexion,Pharmaceuticals, Inc. toda...II studies examining Soliris(TM) (eculizumab) for ...ia (PNH) at the 12th,Congress of European Hematolo...on (EHA) in Vienna. These presentations,included: ...
...ARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory N...liminary data from the,ongoing phase III study for...relin do not support the expected sustainable bloo... in all patients.,Therefore, Ipsen has decided not...n the protocol. No safety concerns have,been obser...
Other Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 2Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 3
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium.
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches.
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches.
Left angled 5 mm blunt hook. Overall length: 9.9 inches.
Medicine Products: